This study included three main findings: (1) plasma lncRNA levels differed in BRAF-mutated advanced melanoma patients and healthy controls; (2) expression levels of selected lncRNA were linked with favorable median PFS and OS of patients treated with BRAF inhibitor; and (3) plasma levels of particular lncRNAs were linked with primary progression of the disease in patients treated with BRAF inhibitor. This evidence concerns the gene BRAF and melanoma.